A reconfigurable DNA framework nanotube-assisted antiangiogenic therapy for effective protection against multi-organ injury

Wei Li,Zhongliang Wang,Qing Su,Qian Wu,Jie Chen,Simin Zhu,J. Li,Hao Wu,Juanhua Zeng,Linlang Guo,Jian He,Chao Zhang

DOI: https://doi.org/10.22541/au.169750094.49338066/v1

2023-01-01

Abstract:With the burgeoning development of antiangiogenic therapy, various of antiangiogenic drugs have been developed and applied to cancer treatment. Nonetheless, for antiangiogenic drugs, the confined tumor targeting ability as well as the nonspecific bio-distribution often compromises the therapeutic outcome and causes serious multi-organ injury. In this study, we programme a reconfigurable DNA framework nanotube (rDFN) for manageable delivery of antiangiogenic drugs to minimize their damage to normal tissues. The fastened tubular structure of rDFN circumvented the direct expose of cargo endostar (Endo), a China Food and Drug Administration-approved antiangiogenic drug, to normal tissues. Meanwhile, the outside bedeck of rDFN with AS1411, a specific DNA aptamer for tumor-overexpressed nucleolin, conferred the encased Endo with greater tumor-targeting ability. Upon entry into tumor sites, nucleolin-responsive fasteners would be opened, allowing the controlled release of Endo. Based on the protective loading and activable unloading of Endo, an amplified anti-tumor effect and a reduced multi-organ injury were concurrently achieved. Conclusively, our work opens a new avenue for reducing antiangiogenic therapy-induced multi-organ injury.